Usually, people get malaria by being bitten by an infective female Anopheles mosquito. Only Anopheles mosquitoes can transmit malaria. Malaria is still common in tropical and subtropical countries. Thus, early diagnosis is necessary. The procedures/examinations that are conducted to identify malarial infection are called as malaria diagnostics. Diagnosis of malaria depends on the demonstration of parasites in blood, usually by microscopy. Microscopy is considered as the gold standard for malaria diagnosis in endemic countries. This method has a sensitivity of 50 to 500 parasites/μl, is inexpensive, and allows the identification of species and parasite density. PCR is most useful for confirming the species of malarial parasite after the diagnosis has been established by either smear microscopy or RDT.
The global malaria diagnostics market is estimated to account for US$ 769.7 Mn in terms of value by the end of 2022.
Government initiatives to prevent malaria is expected to propel the growth of the global malaria diagnostics market during the forecast period. For instance, U.S. President's Malaria Initiative (PMI) is a government initiative designed to drastically reduce malaria deaths and illnesses in target countries in sub-Saharan Africa with a long-term vision of a world without malaria. PMI supports 24 partner countries in sub-Saharan Africa and three programs in the Greater Mekong Sub-region in Southeast Asia to control and eliminate malaria.
High demand for diagnostic tools in malaria-endemic regions is expected to provide significant growth opportunities for player in the malaria diagnostics market over the forecast period. For instance, according to the World Health Organization (WHO), in 2020, there were an estimated 241 million cases of malaria worldwide. The WHO African Region carries a disproportionately high share of the global malaria burden. In 2020, the region was home to 95% of malaria cases and 96% of malaria deaths.
Increasing number of malaria-free countries and high demand for low-cost diagnostic tools are major factors expected to impede growth of the global malaria diagnostics market. For instance, between 2020 and 2022, a total of 12 countries (Morocco, Turkmenistan, Argentina, Paraguay, Sri Lanka, China, Uzbekistan, Armenia, Kyrgyzstan, Algeria, El Salvador, and the United Arab Emirates) have been certified malaria-free by the World Health Organization (WHO).
Moreover, in April 2021, the WHO launched the E-2025 initiative with a goal of eradicating malaria from the 25 countries around the world.
Global Malaria Diagnostics Market - Impact of Coronavirus (Covid-19) Pandemic
Malaria-endemic countries in all WHO have regions have reported cases of COVID-19. In the WHO African Region, which carries more than 90% of the global malaria burden, there have been more than 1 million confirmed cases of COVID-19 since the beginning of the pandemic. Thus, there is an increasing demand for diagnostic kits to detect and treat these two diseases. In February 2022, Kenya's Ministry of Health announced the launch of malaria and COVID-19 PCR diagnostic kits in a bid to boost timely detection and treatment of the two diseases. The kits will save the country and families from importation at a higher price.
To know the latest trends and insights prevalent in the Malaria Diagnostics Market, click the link below:
The global malaria diagnostics market was valued at US$ 729.1 Mn in 2021 and is forecast to reach a value of US$ 1,068.9 Mn by 2028 at a CAGR of 5.6% between 2022 and 2028.
Among technology segment microscopy segment held dominant position in the global malaria diagnostics market in 2021, accounting for 51.5% share in terms of value, increasing approval and launch of new products is expected to propel growth of the segment during the forecast period.
Major players operating in the global malaria diagnostics market include Nikon Corporation, Bio-Rad Laboratories Inc., Siemens Healthineers, BioMérieux, Abbott Laboratories, Access Bio, Thermo Fisher Scientific Inc., Meril Life Sciences Pvt Ltd., Premier Medical Corporation Pvt Ltd., among others.
In November 2020, bioMérieux signed a Memorandum of Understanding with Pfizer to fight against AMR in Singapore by equipping healthcare professionals with specialized knowledge and skills in infectious disease diagnostics.
In April 2019, Human Diagnostics Worldwide, Eiken Chemical Co., Ltd., and the Foundation for Innovative New Diagnostics (FIND) launched the first commercially available molecular diagnostic test for the detection of malaria caused by Plasmodium vivax parasites.